<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00028977</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000069155</org_study_id>
    <secondary_id>UCSF-CRO-00758</secondary_id>
    <secondary_id>UCSF-IND-59521</secondary_id>
    <secondary_id>NCI-G01-2043</secondary_id>
    <nct_id>NCT00028977</nct_id>
  </id_info>
  <brief_title>Herbal Therapy in Treating Women With Metastatic Breast Cancer</brief_title>
  <official_title>A Pilot Safety, Feasibility, Efficacy And Correlative (Phase I/II) Study Assessing Herba Scutellaria Barbatae (HSB) For Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <brief_summary>
    <textblock>
      RATIONALE: The Chinese herb Scutellaria barbata contains ingredients that may slow the growth&#xD;
      of cancer cells and may be an effective treatment for metastatic breast cancer.&#xD;
&#xD;
      PURPOSE: Phase I/II trial to study the effectiveness of Scutellaria barbata in treating women&#xD;
      who have metastatic breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the efficacy of Scutellaria barbata (Chinese herbal extract) in terms of tumor&#xD;
           response in women with metastatic breast cancer.&#xD;
&#xD;
        -  Determine the safety and toxicity of this therapy in these patients.&#xD;
&#xD;
        -  Determine the feasibility of this therapy in these patients.&#xD;
&#xD;
        -  Determine the time to progression, overall survival, and resource utilization of&#xD;
           patients treated with this therapy.&#xD;
&#xD;
        -  Determine the quality of life of patients treated with this therapy.&#xD;
&#xD;
        -  Determine the bioavailability and pharmacokinetics of this therapy in these patients.&#xD;
&#xD;
      OUTLINE: Patients receive oral Scutellaria barbata (Chinese herbal extract) twice daily for&#xD;
      12 months in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Quality of life is assessed at baseline and then every 6 months thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 25 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2001</start_date>
  <completion_date type="Actual">April 2006</completion_date>
  <primary_completion_date type="Actual">April 2006</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Actual">21</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>herba scutellaria barbata</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>herba scutellaria Barbatae (HSB)</intervention_name>
    <other_name>Traditional Chinese Medicine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed breast cancer (may include original primary cancer diagnosis)&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  Metastatic involvement with minimal or no symptoms&#xD;
&#xD;
               -  Solitary metastases require histological confirmation&#xD;
&#xD;
          -  No extensive liver involvement (more than 50% of liver parenchyma)&#xD;
&#xD;
          -  No lymphangitic pulmonary involvement&#xD;
&#xD;
          -  CNS involvement or spinal cord compression allowed if stabilized by therapy for more&#xD;
             than 3 months&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Sex:&#xD;
&#xD;
          -  Female&#xD;
&#xD;
        Menopausal status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  More than 6 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 2,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 75,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Bilirubin no greater than 1.7 mg/dL&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 2.0 mg/dL&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No history of multiple or severe food or medicine allergies&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  At least 1 week since prior biologic therapy&#xD;
&#xD;
          -  No concurrent anticancer biologic therapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 1 week since prior chemotherapy&#xD;
&#xD;
          -  No concurrent anticancer chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  At least 1 week since prior hormonal therapy&#xD;
&#xD;
          -  No concurrent anticancer hormonal therapy&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Recovered from prior anticancer therapy&#xD;
&#xD;
          -  At least 1 week since prior investigational agents&#xD;
&#xD;
          -  At least 1 week since prior herbal medications&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  Concurrent pamidronate allowed&#xD;
&#xD;
          -  Concurrent acupuncture or other nonherbal therapy allowed&#xD;
&#xD;
          -  Concurrent nutritional vitamin supplementation (up to 5 times recommended daily&#xD;
             allowance) allowed&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hope S. Rugo, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Research Network, Incorporated</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <study_first_submitted>January 4, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>September 13, 2012</last_update_submitted>
  <last_update_submitted_qc>September 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

